The Technical Analyst
POINT Biopharma Global [PNT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
POINT Biopharma Global Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.16% $12.50
America/New_York / 26 des 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 332.11 mill |
| EPS: | 1.100 |
| P/E: | 11.36 |
| Earnings Date: | Mar 22, 2024 |
| SharesOutstanding: | 106.57 mill |
| Avg Daily Volume: | 3.85 mill |
| RATING 2023-12-29 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 11.36 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.93x |
| Company: PE 11.36 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.18 - 12.82 ( +/- 2.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-26 | Goodman Jonathan R. | Sell | 41 872 | Common Stock |
| 2023-12-27 | Goodman Jonathan R. | Sell | 35 872 | Stock Option (Right to Buy) |
| 2023-12-27 | Goodman Jonathan R. | Sell | 25 000 | Stock Option (Right to Buy) |
| 2023-12-27 | Goodman Jonathan R. | Sell | 25 614 | Stock Option (Right to Buy) |
| 2023-12-27 | Goodman Jonathan R. | Sell | 44 749 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -77.78 |
| Last 96 transactions |
| Buy: 3 517 450 | Sell: 10 366 533 |
Forecast:
01:40 - $14.81
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.50 (0.16% ) |
| Volume | 3.29 mill |
| Avg. Vol. | 3.85 mill |
| % of Avg. Vol | 85.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PNT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PNT
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Latest Press Releases
2023-12-27 08:31:00 - Press Release
Lilly Completes Acquisition Of Point Biopharma
Indianapolis , dec. 27, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the successful completion of its acquisition of point biopharma global inc. (nasdaq: pnt), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of point," said jacob van naarden, executive vice president and president, loxo@lilly.
2023-12-18 07:30:00 - Press Release
Lantheus And Point Biopharma Announce Positive Topline Results From Pivotal Splash Trial In Metastatic Castration-resistant Prostate Cancer
Phase 3 splash study of 177lu-pnt2002 demonstrated statistically significant improvement in radiographic progression-free survival (rpfs) phase 3 splash study of 177lu-pnt2002 demonstrated statistically significant improvement in radiographic progression-free survival (rpfs)
2023-12-18 06:45:00 - Press Release
Lilly Extends Tender Offer To Acquire Point Biopharma To Dec. 22, 2023
Indianapolis , dec. 18, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("shares") of common stock of point biopharma global inc. (nasdaq: pnt), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. the tender offer, which was previously scheduled to expire at 5:00 p.m.
2023-12-04 06:45:00 - Press Release
Lilly Extends Tender Offer To Acquire Point Biopharma To Dec. 15, 2023
Indianapolis , dec. 4, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("shares") of common stock of point biopharma global inc. (nasdaq: pnt), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. the tender offer, which was previously scheduled to expire at 5:00 p.m.
2023-11-17 06:45:00 - Press Release
Lilly Extends Tender Offer To Acquire Point Biopharma To Dec. 1, 2023
Indianapolis , nov. 17, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("shares") of common stock of point biopharma global inc. (nasdaq: pnt), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. the tender offer, which was previously scheduled to expire at 5:00 p.m.
Latest News
2023-12-27 07:50:00 - Market Watch
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.
2023-12-18 08:54:00 - Market Watch
Lantheus and Point Biopharma shares drop on prostate cancer treatment data
Shares of Lantheus Holdings Inc. LNTH, -2.38% and Point Biopharma Global Inc. PNT, +2.26% fell sharply premarket on Monday after the companies released new data from a trial of their experimental treatment for prostate cancer. The therapy, Lu-PNT2002, met the trial's primary goal, with a median progression-free survival of 9.5 months, compared with six months for patients on an alternative treatment, an androgen receptor pathway inhibitor, the companies said in a release.
2023-12-08 13:32:27 - Zacks Investment Research
POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know
POINT Biopharma Global Inc. (PNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-12-04 07:21:11 - Reuters
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the radiopharma developer.
2023-10-12 16:35:30 - Seeking Alpha
Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, has driven significant revenue growth. Lantheus acquired rights to two radioligand drug candidates from Point Biopharma in 2022, targeting prostate cancer and neuroendocrine tumors.
2023-10-10 12:47:24 - Zacks Investment Research
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
2023-10-05 16:50:42 - The Motley Fool
Why Point BioPharma Global Stock Skyrocketed 86% This Week
On Tuesday, Eli Lilly agreed to acquire Point Biopharma for $12.50 per share in cash -- an 87% premium from Monday's close. The deal isn't subject to financing conditions, but still requires a license transfer approval from the U.S. Nuclear Regulatory Commission as well as the successful tender of a majority of Point's common shares outstanding by Lilly.
2023-10-03 13:52:18 - The Motley Fool
Why Shares of Point Biopharma Global Are Soaring Tuesday
Point Biopharma focuses on oncology therapies. The company's lead therapy is PNT2002 to treat prostate cancer.
2023-10-03 12:00:39 - Investopedia
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting treatments.
2023-10-03 09:05:12 - Proactive Investors
Point Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bid
Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company for $1.4 billion (£1.03 billion). The acquisition allows Lilly to expand its portfolio of experimental cancer therapies, particularly in the area of radioligand treatments.